Skip to main content
Equibles
GMED logo

GMED · Globus Medical Inc · Metrics

Track GMED — free

Use GMED with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GMED.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$78.68 -0.28 (-0.35%) At close · Oct 21
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$10.60B
Shares
134.26M
Volume · Oct 21 1.03M Avg daily vol (3M) 1.43M

GMED metrics

98 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$78.68
Market cap
$10.60B

Price action

20 metrics
Price change (1W)
+3.5%
Price change (30D)
+6.3%
Price change (3M)
+3.8%
Price change (6M)
-15.8%
Price change (YTD)
-9.6%
Price change (1Y)
+28.2%
Trailing year
Price change (5Y)
+1.3%
52-week high
$96.82
52-week low
$60.39
Change from 52-week high
-18.4%
Change from 52-week low
+30.8%
Annualized volatility
48.7%
Annualized volatility (3M)
28.8%
Beta
0.7
RSI (14D)
57.9
Price vs SMA 50
+0.7%
Price vs SMA 200
-5.9%
Avg volume (3M)
1.43M
Relative volume
1.1
Average dollar volume
$112.28M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
134.26M

Valuation

12 metrics
P / E (TTM)
20.3
Trailing earnings · reciprocal yield 4.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.0%
P / book
2.1
reciprocal yield 46.9%
FCF yield
7.4%
TTM · current market cap
Buyback yield
2.2%
P / FCF
13.4
reciprocal yield 7.4%
P / operating cash flow
11.2
reciprocal yield 9.0%
Earnings yield
5.3%

Historical valuation

8 metrics
P / E historical average (3Y)
77.1×
reciprocal yield 1.3%
P / E historical average (5Y)
61.5×
reciprocal yield 1.6%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
20.3%
Trailing 12 months
Net margin
17.0%
Gross profit (TTM)
$1.33B
Operating profit (TTM)
$639.52M
Net income (TTM)
$535.43M
Trailing 12 months
Diluted EPS (TTM)
$3.89
FCF margin
24.0%
Effective tax rate
18.9%

Per share

11 metrics
Revenue per diluted share (TTM)
$22.98
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$4.67
EBITDA per diluted share (TTM)
$6.72
Net income per diluted share (TTM)
$3.91
Operating cash flow per diluted share (TTM)
$6.65
Free cash flow per diluted share (TTM)
$5.52
Capital expenditures per diluted share (TTM)
$1.13
R&D per diluted share (TTM)
$1.07
Stock compensation per diluted share (TTM)
$0.36
Book value per share
$14.05

Growth

11 metrics
Revenue growth YoY
+5.9%
Year over year
Net income growth YoY
-25.3%
Revenue (TTM)
$3.14B
Trailing 12 months
EPS growth YoY
-26.2%
Shares change YoY
+0.6%
Year over year · more shares
Revenue CAGR (3Y)
+42.2%
Revenue CAGR (5Y)
+30.1%
EPS CAGR (3Y)
+28.4%
EPS CAGR (5Y)
+31.2%
FCF CAGR (3Y)
+78.0%
FCF CAGR (5Y)
+34.2%

Quality

14 metrics
Return on equity
11.2%
Return on assets
9.8%
Debt / equity
—
Current ratio
4.6
EBITDA (TTM)
$919.44M
Free cash flow (TTM)
$755.59M
Quick ratio
2.9
Interest coverage
—
Net debt / EBITDA
-0.6
Return on invested capital
—
Trailing 12 months
Net cash
$595.14M
Latest balance sheet
Cash & equivalents
$507.75M
Total assets
$5.49B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$910.39M
Capital expenditures (TTM)
$154.80M
R&D (TTM)
$147.06M
SG&A (TTM)
$1.22B
Stock compensation (TTM)
$48.96M
R&D / revenue
4.7%
Stock compensation / revenue
1.6%

Ownership (13F)

9 metrics
13F filers
606
13F filer change QoQ
-7
Institutional ownership
89.0%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
21.2%
Private-fund adviser ownership
20.4%
Active holders' share change QoQ
+8.4%
Holder tenure
13.8
Price vs estimated holder cost
+7.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.6%

Short interest

3 metrics
Short interest
6.3%
Latest settlement · 5.1 days to cover
Days to cover
5.1d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.41M
Insider-sentiment score
22 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1237831 CUSIP 379577208 13F (30d) 100 filings 91 filers Visit website Investor relations